Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from BioNTech

Pfizer will start charging $110-$130 a dose for COVID vaccines next year

Price increases, while expected, could lead to higher insurance premiums.

Axios

Cancer vaccine being hailed by leading Covid scientists

The husband-and-wife duo who founded BioNTech has made a ‘breakthrough’ in the development of a cancer vaccine

Evening Standard

Cancer vaccine could be available by 2030 thanks to scientists behind Covid jab

The professors said that there was 'a number of breakthroughs' during the Covid vaccine development.

Daily Record

From analysis to the latest developments in health,
read the most diverse news in one place.

'Cancer vaccine' could be available in next 10 years as scientists behind vital jab raise hopes

German couple Professors Ugur Sahin and Ozlem Tureci said they are hesitant to say they can find a cure for cancer, but that they have had “breakthroughs” they will keep working on.

Irish Mirror

Covid vaccine lessons could 'accelerate cancer vaccine' in next 8 years

The founders of coronavirus jab manufacturers BioNTech say developing it gave back to their cancer work

Wales Online

Vaccines to treat cancer possible by 2030, say BioNTech founders

Uğur Şahin and Özlem Türeci say mRNA Covid vaccine technology could be repurposed to help destroy cancer cells

The Guardian - UK

Cancer vaccines will be available within 10 years thanks to Covid jabs, scientists say

Ugur Sahin and Ozlem Tureci, the founders of leading coronavirus vaccine makers BioNTech, have had significant “breakthroughs” in cancer research

Daily Mirror

Read news from The Economist, FT, and more,
with one subscription

Cancer vaccine could be available by 2030, say scientists behind Covid jab

German couple Professors Ugur Sahin and Ozlem Tureci said they have had ‘breakthroughs’ they will keep working on.

The Independent UK

Pfizer, BioNTech Find Updated COVID Booster Protects against Omicron in Trial

Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants of Omicron, generated a strong immune response and was well-tolerated in testing on humans. With the results, which the companies described as consistent with preclinical data, the partners are following up…

Asharq Al-Awsat

mRNA lab deal 'major coup' for Victoria

BioNTech has stuck an in-principle partnership with the Victorian government to establish an mRNA manufacturing facility in Melbourne.

AAP

Did Maravai LifeSciences Deserve to Sell Off on CEO Transition?

The new CEO is a perfect fit for the company's growth plans. Sales will decline sharply anyway.

The Street

‘Like copying a Louis Vuitton handbag’: big pharma hits out at Africa’s replica Covid vaccine

Knowledge-sharing hub in Cape Town reverse engineered the Moderna vaccine, but future of the initiative to reduce inequity remains unsure

The Guardian - UK

Check Out What Whales Are Doing With BNTX

Someone with a lot of money to spend has taken a bullish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Brazil approves Pfizer vaccine for children as young as six months

Brazilian national health regulator Anvisa has approved the COVID-19 vaccine produced by Pfizer and BioNTech for children aged between six months and four years, the government body said in a statement Friday night.

Reuters

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The Silver Lining For Pfizer, Moderna In This Month's IBD/TIPP Poll

Vaccine stocks Pfizer and Moderna could see some upside from their new Covid boosters, according to the September IBD/TIPP Poll.

Asharq Al-Awsat

EU Regulator Backs Pfizer's BA.4/5-Adapted COVID Booster

The European Medicines Agency (EMA) on Monday recommended a COVID-19 booster designed to combat Omicron offshoots BA.4/5, days after endorsing a pair of boosters tailored to target the older BA.1 variant. The latest recommendation is for a so-called bivalent vaccine developed by Pfizer and BioNTech, which targets BA.4/5 as well…

Benzinga

Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia. Spectrum Pharmaceuticals shares traded as high as 3.17 percent, in a range of $1.21 to $1.30 on day volume of 6.8 million…

Evening Standard

Second Covid booster jab approved in UK ahead of winter vaccine programme

It’s the second jab aimed at both the original and Omicron strains of the virus, to be approved in the UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Pfizer, Moderna Dip Despite CDC Green-Light For Updated Covid Shots

The CDC green-lighted updated Covid booster shots from Pfizer with BioNTech and Moderna, but vaccine stocks largely dipped Friday.

Investors Business Daily

Dow Jones, Other Indexes Reverse Lower; Warren Buffett Sells More BYD Stock

A sudden rise in the unemployment rate tempered today's strong payroll numbers.

Investors Business Daily

Will Updated Covid Boosters Save Pfizer, Moderna? The Stocks Say No

Vaccine makers' stocks sank Wednesday despite Food and Drug Administration authorization for their updated Covid booster shots.

Roll Call

FDA greenlights new COVID-19 booster despite limited data - Roll Call

The Food and Drug Administration granted emergency authorization to Pfizer and Moderna for updated COVID-19 booster shots.

Axios

Moderna's COVID vaccine lawsuit looks ahead to future markets

Moderna's COVID vaccine lawsuit looks beyond the pandemic to future markets

AFP

Moderna sues Pfizer, BioNTech over Covid vaccine

Washington (AFP) - Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.

Asharq Al-Awsat

Moderna Sues Pfizer/BioNTech for Patent Infringement over COVID Vaccine

Moderna sued Pfizer and its German partner BioNTech on Friday for patent infringement in the development of the first COVID-19 vaccine approved in the United States, alleging they copied technology that Moderna developed years before the pandemic. Pfizer shares fell nearly 1%, while BioNTech US-listed shares were down about 1.5%…

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

328 stories

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.